The revolutionary trial, KEYNOTE 024, changed the future of chemotherapy in lung cancer, setting back cytotoxic agents to later lines of treatment and approved Pembrolizumab replacing chemotherapy for PD-L1 > 50% patients [64]. This evidence concerns the gene CD274 and lung cancer.